Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 8 | Arthritis Research & Therapy

Figure 8

From: Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop

Figure 8

Binding to chondroitin sulfate chains protects CCL2 from protease-mediated degradation. (A) CCL2 was pre-incubated with chondroitin sulfate (CS) or vehicle, and treated with a series of proteases including elastase, cathepsin G, and trypsin. A representative immunoblot from three different experiments shows a band corresponding to intact CCL2 (10 kDa). (B) Amount of intact CCL2 in individual wells precoated with CS or vehicle, and subsequently treated with a series of proteases. Mean and standard deviation of three independent measurements is shown. The quantity of intact CCL2 in individual samples was expressed as a percentage of the quantity of CCL2 on wells precoated with CS and not treated with protease.

Back to article page